Huntington National Bank Has $1.81 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Huntington National Bank increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 15.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,027 shares of the company’s stock after buying an additional 2,818 shares during the period. Huntington National Bank’s holdings in Novo Nordisk A/S were worth $1,809,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. Massachusetts Financial Services Co. MA grew its holdings in Novo Nordisk A/S by 25.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 100,108 shares of the company’s stock valued at $8,611,000 after buying an additional 20,448 shares in the last quarter. Potomac Fund Management Inc. ADV acquired a new stake in Novo Nordisk A/S in the fourth quarter worth $1,235,000. Trexquant Investment LP increased its stake in Novo Nordisk A/S by 36.6% in the fourth quarter. Trexquant Investment LP now owns 232,246 shares of the company’s stock valued at $19,978,000 after purchasing an additional 62,267 shares in the last quarter. May Hill Capital LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $419,000. Finally, Headlands Technologies LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $893,000. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on NVO shares. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 21st. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $67.08 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a 50-day moving average of $81.36 and a 200-day moving average of $97.26. Novo Nordisk A/S has a one year low of $65.53 and a one year high of $148.15. The company has a market cap of $301.04 billion, a P/E ratio of 20.39, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.